Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edesa Biotech (EDSA) Cash & Equivalents (2016 - 2022)

Edesa Biotech's Cash & Equivalents history spans 10 years, with the latest figure at $12.8 million for Q2 2022.

  • For Q2 2022, Cash & Equivalents rose 59.06% year-over-year to $12.8 million; the TTM value through Jun 2022 reached $12.8 million, up 59.06%, while the annual FY2021 figure was $7.8 million, 8.67% up from the prior year.
  • Cash & Equivalents for Q2 2022 was $12.8 million at Edesa Biotech, down from $15.9 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $15.9 million in Q1 2022 and bottomed at $3.0 million in Q1 2019.
  • The 5-year median for Cash & Equivalents is $6.3 million (2020), against an average of $6.8 million.
  • The largest annual shift saw Cash & Equivalents fell 28.43% in 2018 before it skyrocketed 129.77% in 2020.
  • A 5-year view of Cash & Equivalents shows it stood at $3.4 million in 2018, then increased by 13.66% to $3.8 million in 2019, then skyrocketed by 64.76% to $6.3 million in 2020, then decreased by 6.73% to $5.9 million in 2021, then skyrocketed by 117.81% to $12.8 million in 2022.
  • Per Business Quant, the three most recent readings for EDSA's Cash & Equivalents are $12.8 million (Q2 2022), $15.9 million (Q1 2022), and $5.9 million (Q4 2021).